You are here:

The science
is in the
genes

The magic
is in the
knowledge

The art
is in the
execution

The fun
is in the
culture

LinkedIn-button

About us

Company
profile

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc part of the Utrecht Science Park location Bilthoven. is one of the world’s leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

LinkedIn-button

Our Vision

Reduction of human diseases through innovative vaccine technology

LinkedIn-button

Our Mission

To partner with (non) governmental
agencies and private entities to help
to reduce the disease burden

LinkedIn-button

Intravacc to the point

  • Founded in 2013
  • HQ at Utrecht Science Park Bilthoven
  • Experts in vaccinology
  • Clinical development & manufacturing organization
  • 2000+ m2 state-of the art facilities, incl BSL-2/3 & GMP
  • ISO 9001 certified
  • >140 high qualified employees
  • 50+ customers worldwide
  • 300+ scientific publications in peer reviewed journals

Dr. Jan Groen

Chief Executive Officer

Jan Groen joined Intravacc B.V. in May 2020 as Chief Executive Officer. Previously Jan was the Chief Executive Officer of Novigenix in Switzerland, a privately held immunotranscriptomic diagnostic company and MDxHealth, a Euronext listed genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers. Jan’s career spans over many years in the global biotech industry. Jan was President and COO of Agendia, co-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Center, National Institute of Public Health and Akzo-Nobel. Jan served on the board of several biotech companies. Currently he is chairman of the board of Cergentis, serves on the board of SPL Medical in the Netherlands, Destina Genomics SA in Spain and Angle Ltd in the UK. He holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, and has published over 125 papers in international scientific journals.

Marijke Vendrig, MSc

Manager Quality Affairs

Marijke Vendrig joined Intravacc in 2014. Before joining Intravacc Marijke held several Quality
Assurance (QA) positions within the pharmaceutical industry in Solvay Duphar (1995 – 1997), Fort Dodge Animal Health (1997 – 2004), Netherlands vaccine Institute (2005 – 2012) and Bilthoven Biologicals (2012-2014). She is quite familiar with vaccine production, QC testing and quality systems (EU GMP, ISO9001 and ISO14001). At Intravacc Marijke also act as Qualified Person for investigational medicinal products. She is trained as a Medical Biologist at the University of Utrecht.

Erik Popping, LL.M

General Counsel

Erik Popping joined Intravacc in January 2016. He has more than 14 years of experience within the pharmaceutical / healthcare industry as corporate and legal counsel. Before Erik joined Intravacc, he was Corporate & Legal counsel at the Hal Allergy Group. Prior to that he was the Legal Counsel of the Netherlands Vaccine Institute, a predecessor of Intravacc. He holds a Master’s degree in law (LL.M.) (Radboud University) and a Bachelor degree in business administration (HAN University of applied sciences).

Rob van Zeeland, RA

Chief Financial Officer

Rob van Zeeland RA joined Intravacc as Chief Financial Officer in 2014. Prior to joining Intravacc Rob held various international positions in the field of finance. His last position was with Danaher Corporation, a NYSE listed company active in life sciences, diagnostics and environmental businesses. Rob served as CFO for Ormco EMEA, a leading Orthodontic organization, EMEA for Fluke Test and Measurement, EMEA for Danaher Motion and was group controller for Videojet, a world leader in product identification. He played a key role in several acquisitions and business integrations. Before working as a financial professional in the business industry, Rob developed his career as an Audit Manager with the Big 4. Rob is a Registered Accountant in the Netherlands.

Daniëlle Lankveld, DVM, PhD

Chief Operating Officer

Daniëlle is Chief Operational Officer of Intravacc since 2017. As a doctor in veterinary medicine she started her career in 1995 as a resident in equine surgery at the former Department of General and Large Animal Surgery of the Utrecht University. After completing this she continued her career as a veterinary anesthetist for the same department and obtained her PhD in 2007. In this year she moved to the National Institute of Public Health to work as both a researcher in nanotoxicology and an assessor of human medical dossiers for cardiovascular medicine. In 2011 Daniëlle became Manager of the Animal Research Center of the former Netherlands Vaccine Institute and member of the management team. In 2013, when the Animal Research Center became part of Intravacc, Daniëlle moved to the position of Chief Development Officer until 2017 when she became the COO.

Minke Wessels, MA

HR Manager

Minke Wessels joined Intravacc in September 2019. She brings more than 15 years of HR experience to Intravacc. After her Master degree in International Law at Leiden University, she started out as Team manager at the ING Bank. Five years into the job she chose a new career path within HR, to pursue her interests in individual & group development and change management. Before joining Intravacc, she was Sr. HR Business Partner at Nationale-Nederlanden. Minke is an experienced coach and trainer and she has a track record in creating a culture of collaboration and managing change.

Michiel Stork, PhD.

Vice President Business Development

Michiel started his current position as VP business development in July 2020 and works at Intravacc for over 9 years. Trained in molecular microbiology he first came in contact with vaccines in 2005. He worked in this field ever since. He started with antigen discovery and animal models followed by vaccine design and process development. This allowed him to work on the complete chain from lead finding up to clinical trials. Prior to his current position he was head of the Process Development Bacterial Vaccine department at Intravacc, where he focused on the design and upscaling of processes for conjugate and vesicle vaccines. During this time he studied the biogenesis of outer membrane vesicle vaccines to unravel the mechanism of formation and subsequent yield increases.

Elly van Riet

Vice President Research & Development

Elly has been working at Intravacc since 2013, and has been Vice-President of R&D since November 2020. She earned her MSc as an engineer in biotechnology at Wageningen University and Research Centre, followed by a PhD in immunology at the Department of Parasitology at Leiden University Medical Centre. During her PhD she got involved in vaccine research when she studied the effect of helminth infections on the immune responses to vaccination in Gabonese children. She continued vaccine related research as a postdoc at the Leiden Academic Centre for Drug Research where she was involved in designing nanoparticle vaccines for transcutaneous and intranasal delivery. She was granted a postdoctoral fellowship to investigate human immune responses to intranasal administration of influenza vaccines at the Influenza Virus Research Center of the National Institute of Infectious Diseases in Tokyo. In 2013 she joined Intravacc as Head of the department of Clinical Development.

Dinja Oosterhoff

Program Director

Dinja Oosterhoff is the Program Director of Intravacc since October 2020. Following her MSc in Medical Biology at the VU University in Amsterdam, she obtained her PhD in 2005 at the VU University Medical Center, Department of Medical Oncology on the development of adenovirus-based gene therapy vectors for the treatment of solid tumors. Hereafter Dinja worked for several years on immunotherapy projects and the development of dendritic cell targeted anti-cancer vaccines. She started working at Intravacc in 2013, where she has been leading various projects on the development of innovative non-polio enteroviral vaccines, like a multivalent vaccine to prevent Hand, Foot, Mouth Disease. Prior to her current position, Dinja worked as Program Manager Viral Vaccines.

LinkedIn-button

About us

Latest News

Press Release

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our primary goal to restyle Intravacc was to demonstrate our aspiration to become a meaningful organization…

Intravacc 2.0
  • New website and branding
  • Matches Intravacc’s aspiration to become a leading vaccine CDMO
  • We welcome your feedback on our new website
Read more

Press Release

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of…

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
  • Growing concerns about global spread of this respiratory enterovirus
  • Vaccine to protect children from Acute Flaccid Myelitis
  • Development of inactivated EV D68 vaccine, through to Phase I clinical testing
Read more

Press Release

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the world’s first prophylactic vaccine against gonorrhea, NGoXIM. For this…

Intravacc and Therapyx jointly develop the world's first prophylactic gonorrhea vaccine
  • Gonorrhea is the second most common bacterial infectious disease worldwide
  • Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
  • Induce an adaptive immune response for long term protection against the gonorrhea bacteria
  • Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza
Read more
LinkedIn-button

About us

Media

LinkedIn-button

About us

Join our Community

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.